AURA3, an open-label, randomized phase III study, was performed to assess the efficacy and safety of osimertinib versus platinum-based doublet chemotherapy in patients with advanced NSCLC that were positive for the T790M mutation of EGFR that had progressed during previous EGFR-TKI therapy [13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.